Effectiveness & Safety of Desloratadine in Patients With Allergic Airway

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This was a placebo controlled study designed to evaluate the effectiveness of desloratadine in relieving symptoms of allergic airway disease during the pollen season. Patients received desloratadine 10 mg or placebo once daily for 28 days, and had their allergy symptoms and side effects to medication measured on Day 1, Day 15, and Day 29 (one day after stopping study drug).

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00882115` - Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose	N/A
	Recruiting	`NCT00032526` - Classical Conditioning to Treat Allergic Airway Diseases	N/A

NCT number	NCT00779636
Study type	Interventional
Source	Organon and Co
Contact
Status	Completed
Phase	Phase 4
Start date	July 1, 2003
Completion date	November 1, 2004

Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms